These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24063248)

  • 1. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
    Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
    BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.
    Munk M; Memon A; Poulsen SS; Borre M; Nexo E; Sorensen BS
    Scand J Clin Lab Invest; 2013 Sep; 73(6):503-13. PubMed ID: 24015958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
    Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer.
    Guo Y; Duan Z; Jia Y; Ren C; Lv J; Guo P; Zhao W; Wang B; Zhang S; Li Y; Li Z
    Oncol Lett; 2018 May; 15(5):6629-6635. PubMed ID: 29616125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.
    Fujiwara S; Hung M; Yamamoto-Ibusuk CM; Yamamoto Y; Yamamoto S; Tomiguchi M; Takeshita T; Hayashi M; Sueta A; Iwase H
    Oncotarget; 2014 Jun; 5(11):3919-30. PubMed ID: 25003574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.
    Muraoka-Cook RS; Sandahl MA; Strunk KE; Miraglia LC; Husted C; Hunter DM; Elenius K; Chodosh LA; Earp HS
    Mol Cell Biol; 2009 Sep; 29(18):4935-48. PubMed ID: 19596786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.
    Feng SM; Muraoka-Cook RS; Hunter D; Sandahl MA; Caskey LS; Miyazawa K; Atfi A; Earp HS
    Mol Cell Biol; 2009 Feb; 29(3):892-906. PubMed ID: 19047365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
    Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
    Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
    Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH
    Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
    Sassen A; Diermeier-Daucher S; Sieben M; Ortmann O; Hofstaedter F; Schwarz S; Brockhoff G
    Breast Cancer Res; 2009; 11(4):R50. PubMed ID: 19624808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo.
    Nielsen TO; Sorensen S; Dagnæs-Hansen F; Kjems J; Sorensen BS
    Br J Cancer; 2013 Jun; 108(11):2291-8. PubMed ID: 23695025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester.
    Elenius K; Corfas G; Paul S; Choi CJ; Rio C; Plowman GD; Klagsbrun M
    J Biol Chem; 1997 Oct; 272(42):26761-8. PubMed ID: 9334263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
    Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
    J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
    Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance.
    Wei Z; Sijia F; Rui T; Yang L; Jianjun H; Bin W; Jing X
    Ann Diagn Pathol; 2021 Dec; 55():151834. PubMed ID: 34610510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.